Blog

Jaisim Shah

August 21, 2025
Posted by Ulisses

Jaisim Shah has over 30 years industry success in leading product development & commercializing innovative therapies and creating companies with documented success in development and commercialization of some of today’s most recognized...

Suketu D. Desai, PhD

October 2, 2025
Posted by Jitendra

Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suketu is Interim Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC, and...

27 Feb

Press Release

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

February 27, 2024
Posted by Ulisses

PALO ALTO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

26 Feb

Press Release

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

February 27, 2024
Posted by Ulisses

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

26 Feb

Press Release

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone – Over One Million Patients Treated Since its Launch – and Two Additional Milestones Met

February 27, 2024
Posted by Ulisses

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and...

20 Feb

Press Release

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

February 23, 2024
Posted by Ulisses

The lifetime prevalence of neck pain in the adult population is estimated to range from 14.2% to 71% with a mean of 48.5%.2 There are currently no approved medical treatments for neck pain in...

08 Jan

Press Release

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

February 23, 2024
Posted by Jitendra

02 Jan

Press Release

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

January 2, 2024
Posted by Jitendra

26 Dec

Press Release

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

December 27, 2023
Posted by Jitendra

20 Dec

Press Release

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

December 27, 2023
Posted by Jitendra

Jaisim Shah

Suketu D. Desai, PhD

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone – Over One Million Patients Treated Since its Launch – and Two Additional Milestones Met

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

Henry Ji, PhD

Stephen Ma

Dorman Followwill

Alexander Wu, PhD

Jay Chun, MD, PhD